Skip to main content
Premium Trial:

Request an Annual Quote

Roche Extends Cancer Screening Project with Epigenomics

NEW YORK, March 23 (GenomeWeb News) - Epigenomics and Roche Molecular Diagnostics have extended by 18 months their collaboration on cancer screening products, the companies said yesterday in a statement.

 

Roche has agreed to extend a license it took from Epigenomics in December on a panel of markers for colorectal cancer screening, and it will continue working on the validation of breast and prostate screening products, the companies said.

 

Under the terms of the agreement, Epigenomics will take over sensitivity validation for its screening tests for colorectal, prostate, and breast cancer, the companies said.

 

The colorectal cancer screening project is scheduled to continue until the end of the year, the prostate cancer screening project is scheduled to last until at least Oct. 15, and the breast cancer screening project is scheduled to last until at least March 30, 2007, the companies said.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.